Twenty-eight patients with atrial fibrillation of less than 1 month's duration were given a single intravenous bolus of flecainide (2 mg/kg The use of intravenous flecainide should avoid the need for electrical DC conversion even in sick patients. Failure of conversion is associated with covert underlying predisposing factors and duration of atrial fibrillation of more than 72 hours.
Introduction
Atrial fibrillation is common and its incidence increases with age.' It is an inefficient rhythm because its onset is associated with the loss of synchronous atrio-ventricular contraction; cardiac output may be reduced by up to 50% in some subjects.2 It is associated with a significant increase in systemic embolism.3 Thus, cardioversion of all patients with atrial fibrillation should be considered. Where there is a persisting underlying cause (for example mitral valve disease) cardioversion is unlikely to be successful in the long term and management in these cases is aimed at control of the ventricular rate.
The most effective method of cardioversion is electrical DC counter shock. However, this technique requires a general anaesthetic and therefore carries a measurable morbidity. It requires the skills of an anaesthetist, which may be a limited resource. Pharmacological cardioversion of atrial fibrillation has been disappointing. Digoxin given intravenously and oral quinidine, for example, were successful in less than 50% of cases,4-6 whereas verapamil was successful in less than 10%.7 More recently, flecainide, a class 1c antiarrhythmic drug, has been shown to be much more effective in converting supraventricular arrhythmias including atrial fibrillation.7'8 Previous studies have suggested that long standing atrial fibrillation is less successfully cardioverted. We report our experience with intravenous flecainide in patients with atrial fibrillation of recent onset.
Methods
Twenty-eight consecutive patients with atrial fibrillation of less than one month's duration took part in the study. All were in-patients at the time and had been selected for attempted electrical cardioversion. None had clinical evidence of heart failure nor any clinically apparent untreated underlying conditions (for example thyrotoxicosis; mitral valve disease) likely to render cardioversion ineffective. All had a chest X-ray and a 12-lead electrocardiograph and over half (19) Appropriate statistical methods were used to assess differences between subgroups.
Results
Twenty of the 28 patients were male. The average age of the group was 61 years (range 20-79). All had atrial fibrillation and one also had episodes of atrial flutter. Flecainide was successful in 19 patients (68%). Eighteen of these 19 had atrial fibrillation for less than 72 hours and only one patient with atrial fibrillation of less than 72 hours failed to cardiovert. The success rate in this early group was 95%. In all cases the cardioversion occurred within 2 hours of the start of the infusion and mean time to cardioversion was 24 minutes. Only one of the 9 patients with atrial fibrillation of duration more than 72 hours and less than one month converted to sinus rhythm and this occurred at 24 hours, which may not have been a direct effect of the drug. The infusion was well tolerated by all patients and no side effects were reported. In one case a 2 second asystolic pause occurred during the infusion but this required no treatment. No embolic phenomena were seen in either group.
Cause ofatrialfibrillation
The causes of the atrial fibrillation in the early and late groups are shown on Table I . Hypertension and ischaemic heart disease were commonly associated with atrial fibrillation in both groups. In the late group, 2 patients were found to have biochemical evidence of thyrotoxicosis despite being clinically euthyroid; both failed to cardiovert. In 3 patients chronic obstructive airways disease or emphysema were associated with the atrial fibrillation and flecainide was unsuccessful in all these cases also. In the early group, 6 post-operative patients developed atrial fibrillation, (1 as a consequence of acute pulmonary embolism). Three of these patients were very ill and ventilated at the time and two developed atrial fibrillation as part of a septicaemic episode. Four patients developed atrial fibrillation within 48 hours of an acute myocardial infarction and one patient developed atrial fibrillation during treadmill testing for angina. In 2 patients high alcohol intake was associated with the onset of atrial fibrillation. All patients in the early group, except one with atrial fibrillation following a sub-endocardial myocardial infarction, were successfully cardioverted with an intravenous bolus of flecainide. In all cases the cardioversion was associated with haemodynamic improvement even in those patients on ventilators. In no patient did flecainide cause haemodynamic deterioration.
Ten patients (53%) in the early group in which cardioversion with flecainide was successful were taking predominantly cardioactive drugs including digoxin (3), calcium antagonists (6) and beta adrenoreceptor blockers (3), compared with 6 (67%) patients in the late group (digoxin 4; beta adrenoreceptor blockers 1; amiodarone 1). Nine of 19 (47%) of the early group and 3 of 9 (33%) of the late group were not taking any form of concomitant anti-arrhythmic therapy (P = not significant, exact test).
Details of the initial heart rate, chest X-ray and echocardiograms are shown in Table II flecainide falls with duration of the arrhythmia. Goy et al.,8 in a study involving 69 patients with atrial fibrillation, found a cardioversion rate of 79% in patients of less than 10 days duration compared with 38% in patients with atrial fibrillation of longer duration. Suttorp et al.,7 in a study of 32 patients, found a conversion rate of 86% in patients with the arrhythmia of less than 24 hours duration, compared with 40% in patients with atrial fibrillation of more than 24 hours duration. Our data shows a cut off at 72 hours duration, with a very low conversion rate of only 14% in patients with atrial fibrillation of longer duration.
Other factors which have been associated with failure of cardioversion with flecainide include increased left atrial dimension.8 This was also shown in our study. However, we believe atrial fibrillation is associated with an increase in left atrial dimension as a consequence of the arrhythmia itself. Indirect evidence to support this is provided by our echo data which show that those patients with atrial fibrillation of less than 72 hours duration have smaller left atrial diameter than those with atrial fibrillation more than 72 hours duration. We suggest that the longer the duration of atrial fibrillation the larger the left atrial dimension and the less likely that successful cardioversion will be achieved. For this reason longstanding atrial fibrillation is rarely successfully cardioverted. Following cardioversion from atrial fibrillation atrial contraction gradually improves over one month as detected by Doppler measures of transmitral blood flow,9 suggesting that left atrial tone takes some time to return to normal. Because of the relationship between atrial fibrillation and atrial dilatation it is important to attempt cardioversion as soon as possible once the arrhythmia has developed. However, it is equally important to correct other underlying predisposing conditions. In the late group 2 patients had biochemical evidence of thyrotoxicosis (normal T4, T3 but suppressed high sensitivity TSH) and both have had radioiodine treatment, and 3 patients had longstanding chest disease. Under these circumstances cardioversion is less likely to be successful because its precipitating underlying cause is still present.
The use of flecainide for ventricular arrhythmias following acute myocardial infarction has recently been discouraged because ofworries over its safety. These worries concern the known proarrhythmic effects of class 1 agents especially in the presence of impaired left ventricular function. In the CAST study'" the drug was given chronically in its oral
form. An intravenous bolus ofthe drug is less likely to be associated with morbidity and has been used extensively and been found to be well tolerated and safe, as in our study.
In conclusion we have found intravenous flecainide (2 mg/kg) to be a safe and effective treatment for cardioversion of atrial fibrillation of less than 72 hours duration. Its use should avoid the need for DC cardioversion in these cases. Failure of cardioversion is associated with covert underlying predisposing factors and duration of atrial fibrillation of more than 72 hours.
